Biotech

In a new report, UBS analyst Matthew Roden discusses the firm’s bullish outlook for biotech stocks. Biotech has had a strong run so far this year, but Roden still sees gas in the tank for several names. Three Drivers UBS sees three drivers for biotech outperformance in the second half...

Biotech analysts at Piper Jaffray stated in a note on Wednesday that "we are buyers on weakness" of select biotech names that boast strong enough balance sheets to "make it through" upcoming value-driving events. The analysts, led by Edward Tenthoff, singled out Vertex Pharmaceuticals Incorporated...

Biotech stocks are among the most volatile and investors are constantly looking towards Wall Street for top notch research and analysis. Michael King of JMP Securities hosted an investor call with Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)'s management team and discussed revusiran...

Do you think we're in a biotech bubble? Find out how you can join the experts in a discussion about the most profitable investments in the biotechnology and pharmaceutical sectors here. Let's be honest: biotech is hot right now. But investors might be wondering where to find more...

Get ready for our #BestofBiotech show featuring biotech traders and experts like TheStreet's Adam Feuerstein on this week's #PreMarket Prep! Be sure to tune in at 8:00 a.m. EST Monday-Friday here interact with our veteran traders, market technicians and money managers that come on...

It was reported on Friday that fourth quarter gross domestic product expanded at a 2.2 percent annual rate, missing consensus expectation of a 2.4 percent gain.  In addition, after-tax corporate profits declined 1.6 percent last quarter, which could signal the far reaching effects of a...

In a report published Tuesday, Leerink analyst Alice Avanian commented that "binary events" in healthcare can be key determinants of performance and that the upcoming Supreme Court decision is an "overhang" for hospital stocks. Here is a list of 18 companies the analyst is...